Author
Listed:
- Sara Ibrahim Hemmo
(Department of Applied Pharmaceutical Sciences and Clinical Pharmacy, Faculty of Pharmacy, Isra University, Amman 11622, Jordan
Sara Ibrahim Hemmo and Abdallah Y. Naser have equal contribution in this study.)
- Abdallah Y. Naser
(Department of Applied Pharmaceutical Sciences and Clinical Pharmacy, Faculty of Pharmacy, Isra University, Amman 11622, Jordan
Sara Ibrahim Hemmo and Abdallah Y. Naser have equal contribution in this study.)
- Hassan Alwafi
(Faculty of Medicine, Umm Alqura University, Mecca 21514, Saudi Arabia)
- Munthir M. Mansour
(Department of Internal Medicine, University of Arkansas for Medical Center, Little Rock, AR 72205, USA)
- Abeer F. R. Alanazi
(Department of Pharmaceutical and Biological Sciences, UCL School of Pharmacy, London WC1E 6BT, UK)
- Zahraa Jalal
(School of Pharmacy, Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT, UK)
- Zahra Khalil Alsairafi
(Department of Pharmacy Practice, Kuwait University, Kuwait 12037, Kuwait)
- Vibhu Paudyal
(School of Pharmacy, Institute of Clinical Sciences, University of Birmingham, Birmingham B15 2TT, UK)
- Esra’a Alomari
(Department of Applied Pharmaceutical Sciences and Clinical Pharmacy, Faculty of Pharmacy, Isra University, Amman 11622, Jordan)
- Hamzeh Al-Momani
(Department of Pediatric, School of Medicine, Hashemite University, Zarqa 13133, Jordan)
- Emad M. Salawati
(Family Medicine Department, Faculty of Medicine, King Abdulaziz University, Jeddah 22254, Saudi Arabia)
- Mohammed Samannodi
(Faculty of Medicine, Umm Alqura University, Mecca 21514, Saudi Arabia)
- Mohammad S. Dairi
(Faculty of Medicine, Umm Alqura University, Mecca 21514, Saudi Arabia)
- Abdel Qader Al Bawab
(Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman 11733, Jordan)
- Moaath K. Mustafa Ali
(Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD 20742, USA)
- Saqer Alkharabsheh
(Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH 44195, USA)
Abstract
Objectives: The aim of this study was to explore the trend of ischemic heart disease (IHD) admission and the prescriptions of IHD medications in England and Wales. Methods: A secular trends study was conducted during the period of 1999 to 2019. We extracted hospital admission data for patients from all age groups from the Hospital Episode Statistics database in England and the Patient Episode Database for Wales. Prescriptions of IHD medications were extracted from the Prescription Cost Analysis database from 2004 to 2019. The chi-squared test was used to assess the difference between the admission rates and the difference between IHD medication prescription rates. The trends in IHD-related hospital admission and IHD-related medication prescription were assessed using a Poisson model. The correlation between hospital admissions for IHD and its IHD medication-related prescriptions was assessed using the Pearson correlation coefficient. Results: Our study detected a significant increase in the rate of cardiovascular disease (CVD) medication prescriptions in England and Wales, representing a rise in the CVD medications prescription rate of 41.8% (from 539,334.95 (95% CI = 539,286.30–539,383.59) in 2004 to 764,584.55 (95% CI = 764,545.55–764,623.56) in 2019 prescriptions per 100,000 persons), with a mean increase of 2.8% per year during the past 15 years. This increase was connected with a reduction in the IHD hospital admission rate by 15.4% (from 838.50 (95% CI = 836.05–840.94) in 2004 to 709.78 (95% CI = 707.65–711.92) in 2019 per 100,000 persons, trend test, p < 0.01), with a mean decrease of 1.02% per year during the past 15 years and by 5% (from 747.43 (95% CI = 745.09–749.77) in 1999 to 709.78 (95% CI = 707.65–711.92) in 2019 per 100,000 persons, trend test, p < 0.01) with a mean decrease of 0.25% per year during the past two decades in England and Wales. Conclusion: The rate of hospitalisation due to IHD has decreased in England and Wales during the past two decades. Hospitalisation due to IHD was strongly and negatively correlated with the increase in the rates of dispensing of IHD-related medications. Other factors contributing to this decline could be the increase in controlling IHD risk factors during the past few years. Future studies exploring other risk factors that are associated with IHD hospitalisation are warranted.
Suggested Citation
Sara Ibrahim Hemmo & Abdallah Y. Naser & Hassan Alwafi & Munthir M. Mansour & Abeer F. R. Alanazi & Zahraa Jalal & Zahra Khalil Alsairafi & Vibhu Paudyal & Esra’a Alomari & Hamzeh Al-Momani & Emad M. , 2021.
"Hospital Admissions Due to Ischemic Heart Diseases and Prescriptions of Cardiovascular Diseases Medications in England and Wales in the Past Two Decades,"
IJERPH, MDPI, vol. 18(13), pages 1-19, July.
Handle:
RePEc:gam:jijerp:v:18:y:2021:i:13:p:7041-:d:586559
Download full text from publisher
Citations
Citations are extracted by the
CitEc Project, subscribe to its
RSS feed for this item.
Cited by:
- Abeer F. R. Alanazi & Abdallah Y. Naser & Prisca Pakan & Atheer F. Alanazi & Alyamama Abdulaziz A. Alanazi & Zahra Khalil Alsairafi & Fatemah M. Alsaleh, 2021.
"Trends of Hospital Admissions Due to Congenital Anomalies in England and Wales between 1999 and 2019: An Ecological Study,"
IJERPH, MDPI, vol. 18(22), pages 1-21, November.
- Abdallah Y. Naser & Hamzeh Mohammad Alrawashdeh & Hassan Alwafi & Amal Khaleel AbuAlhommos & Zahraa Jalal & Vibhu Paudyal & Zahra Khalil Alsairafi & Emad M. Salawati & Mohammed Samannodi & Kanar Sweis, 2021.
"Hospital Admission Trends Due to Viral Infections Characterised by Skin and Mucous Membrane Lesions in the Past Two Decades in England and Wales: An Ecological Study,"
IJERPH, MDPI, vol. 18(21), pages 1-18, November.
- Abdallah Y. Naser & Hassan Alwafi & Sara Ibrahim Hemmo & Hamzeh Mohammad Alrawashdeh & Jaber S. Alqahtani & Saeed M. Alghamdi & Moaath K. Mustafa Ali, 2022.
"Trends in Hospital Admissions Due to Neoplasms in England and Wales between 1999 and 2019: An Ecological Study,"
IJERPH, MDPI, vol. 19(13), pages 1-14, June.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:18:y:2021:i:13:p:7041-:d:586559. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.